302 related articles for article (PubMed ID: 21240487)
1. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Durgan K; Ali M; Warner P; Latchman YE
Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
[TBL] [Abstract][Full Text] [Related]
2. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
Akbari O; Stock P; Singh AK; Lombardi V; Lee WL; Freeman GJ; Sharpe AH; Umetsu DT; Dekruyff RH
Mucosal Immunol; 2010 Jan; 3(1):81-91. PubMed ID: 19741598
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.
Parekh VV; Lalani S; Kim S; Halder R; Azuma M; Yagita H; Kumar V; Wu L; Kaer LV
J Immunol; 2009 Mar; 182(5):2816-26. PubMed ID: 19234176
[TBL] [Abstract][Full Text] [Related]
5. B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells.
Brandl C; Ortler S; Herrmann T; Cardell S; Lutz MB; Wiendl H
PLoS One; 2010 May; 5(5):e10800. PubMed ID: 20520738
[TBL] [Abstract][Full Text] [Related]
6. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
8. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.
Reynoso ED; Elpek KG; Francisco L; Bronson R; Bellemare-Pelletier A; Sharpe AH; Freeman GJ; Turley SJ
J Immunol; 2009 Feb; 182(4):2102-12. PubMed ID: 19201863
[TBL] [Abstract][Full Text] [Related]
9. Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy.
Chang WS; Kim JY; Kim YJ; Kim YS; Lee JM; Azuma M; Yagita H; Kang CY
J Immunol; 2008 Nov; 181(10):6707-10. PubMed ID: 18981087
[TBL] [Abstract][Full Text] [Related]
10. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.
Tohn R; Blumenfeld H; Haeryfar SM; Veerapen N; Besra GS; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2011 Apr; 164(1):26-41. PubMed ID: 21361909
[TBL] [Abstract][Full Text] [Related]
13. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.
Martin-Orozco N; Wang YH; Yagita H; Dong C
J Immunol; 2006 Dec; 177(12):8291-5. PubMed ID: 17142723
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
15. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.
Stolk DA; de Haas A; Vree J; Duinkerken S; Lübbers J; van de Ven R; Ambrosini M; Kalay H; Bruijns S; van der Vliet HJ; de Gruijl TD; van Kooyk Y
Front Immunol; 2020; 11():990. PubMed ID: 32536918
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.
Vezys V; Penaloza-MacMaster P; Barber DL; Ha SJ; Konieczny B; Freeman GJ; Mittler RS; Ahmed R
J Immunol; 2011 Aug; 187(4):1634-42. PubMed ID: 21742975
[TBL] [Abstract][Full Text] [Related]
18. Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection.
Seo SK; Jeong HY; Park SG; Lee SW; Choi IW; Chen L; Choi I
Immunology; 2008 Jan; 123(1):90-9. PubMed ID: 17971153
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
[TBL] [Abstract][Full Text] [Related]
20. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.
Keir ME; Freeman GJ; Sharpe AH
J Immunol; 2007 Oct; 179(8):5064-70. PubMed ID: 17911591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
